Kynurenine 3-monooxygenase is an
enzyme that in humans is encoded by the KMOgene.[5][6]
Kynurenine 3-monooxygenase (KMO; EC 1.14.13.9) is an NADPH-dependent flavin monooxygenase that catalyzes the hydroxylation of the L-
tryptophan metabolite L-
kynurenine to form L-3-hydroxykynurenine.[supplied by OMIM][6] This is the first step in the degradation of Kyneurinine to
Quinolinic acid. This pathway is involved in the activation of cytokine mediated changes in behavior due to inflammatory stimuli such as infections.[7] The KMO gene is upregulated in the lung parenchyma of smokers. [8]
Stone TW, Darlington LG (2002). "Endogenous kynurenines as targets for drug discovery and development". Nature Reviews. Drug Discovery. 1 (8): 609–20.
doi:
10.1038/nrd870.
PMID12402501.
S2CID19203349.
Ligam P, Manuelpillai U, Wallace EM, Walker D (2005). "Localisation of indoleamine 2,3-dioxygenase and kynurenine hydroxylase in the human placenta and decidua: implications for role of the kynurenine pathway in pregnancy". Placenta. 26 (6): 498–504.
doi:
10.1016/j.placenta.2004.08.009.
PMID15950064.
Halford S, Freedman MS, Bellingham J, et al. (2001). "Characterization of a novel human opsin gene with wide tissue expression and identification of embedded and flanking genes on chromosome 1q43". Genomics. 72 (2): 203–8.
doi:
10.1006/geno.2001.6469.
PMID11401433.